<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04766450</url>
  </required_header>
  <id_info>
    <org_study_id>NAC in DPN</org_study_id>
    <nct_id>NCT04766450</nct_id>
  </id_info>
  <brief_title>Effect of High-Dose NAC on Patients With DPN</brief_title>
  <acronym>NAC</acronym>
  <official_title>Effect of High-Dose N-acetyl Cysteine (NAC) on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy (DPN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is to evaluate the efficacy and safety of high dose oral NAC&#xD;
      (2400 mg/day divided into two doses) as an adjunct therapy on oxidative stress, inflammatory&#xD;
      markers and clinical outcome in patients with type 2 diabetes suffering from diabetic&#xD;
      peripheral neuropathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient written informed consent will be taken prior to study conductance&#xD;
&#xD;
        -  Lab assessment will be done at baseline and at the end of the study by withdrawing 7 ml&#xD;
           of whole blood for assessment of following parameters: HbA1c, Liver &amp; renal functions&#xD;
&#xD;
        -  Inflammatory markers including: Human Nuclear factor erythroid 2-related factor (NRF2) &amp;&#xD;
           Tumor necrosis factor alpha (TNF-α) using ELISA Kit&#xD;
&#xD;
        -  Oxidative stress markers: Glutathione Peroxidase using ELISA Kit&#xD;
&#xD;
      Inflammatory and oxidative stress marker samples will be stored at -80 for further evaluation&#xD;
      using ELISA kit at the end of the study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Human Nuclear factor erythroid 2-related factor (NRF2)</measure>
    <time_frame>change from baseline Human Nuclear factor erythroid 2-related factor at 3 months</time_frame>
    <description>Inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of Tumor necrosis factor alpha</measure>
    <time_frame>Change from baseline tumor necrosis factor alpha at 3 months</time_frame>
    <description>Inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of Glutathione peroxidase</measure>
    <time_frame>Change from baseline glutathione peroxidase at 3 months</time_frame>
    <description>Oxidative stress markers</description>
  </primary_outcome>
  <other_outcome>
    <measure>Michigan neuropathy screening instrument.</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>Questionnaire of 15 yes or no questions. score of 13 or more means more neuropathic symptoms</description>
  </other_outcome>
  <other_outcome>
    <measure>Toronto clinical scoring system</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>Questionnaire. as score increase means symptoms increase</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetic Neuropathies</condition>
  <arm_group>
    <arm_group_label>Group 1, NAC group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1, NAC group (n=30): Patients will receive conventional therapy for diabetic neuropathy in addition to High Dose N-acetyl cysteine (2400 mg/day divided into two doses) daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2, Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group 2, Control group (n= 30): Patients will receive conventional therapy for diabetic neuropathy alone for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetyl cysteine</intervention_name>
    <description>NAC exhibits potent anti-oxidant activity in the cell through augmentation of intracellular GSH, which is a major component of the pathways by which cells are protected from OTS, and its direct scavenging activity of free radicals by providing sulfhydryl groups. Additionally, NAC treatment exhibits anti-inﬂammatory effects via inhibition of NF-κB activation and reducing subsequent cytokine production . Mitochondria-protective mechanisms of NAC may also be related to its anti-oxidant and anti-inﬂammatory properties</description>
    <arm_group_label>Group 1, NAC group</arm_group_label>
    <other_name>N-acetyl cysteine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females aged 18-50 years diagnosed with Type 2 Diabetes taking oral&#xD;
             hypoglycemic with controlled at HbA1c (6%-7%.)&#xD;
&#xD;
          2. Patients diagnosed with Diabetic Neuropathy (by pinprick, temperature probe, ankle&#xD;
             reflex, and vibration perception (128-Hz tuning fork) or pressure sensation (10 g&#xD;
             monofilament test).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with acute and chronic inflammatory conditions, consuming any antioxidant&#xD;
             supplements or anti-inflammatory medicines.&#xD;
&#xD;
          2. Pregnancy or lactation or expecting to get pregnant during the study.&#xD;
&#xD;
          3. Medical, psychological, or pharmacological factors interfering with the collection or&#xD;
             interpretation of study data.&#xD;
&#xD;
          4. Cancer patients.&#xD;
&#xD;
          5. Anyone having hypersensitivity to N-acetylcysteine.&#xD;
&#xD;
          6. Anyone already taking N-acetylcysteine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lamia El Wakeel, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherien Emara, TA</last_name>
    <phone>01154089169</phone>
    <email>sherienemara@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Farid Mohamed, Lecturer</last_name>
  </overall_contact_backup>
  <link>
    <url>https://doi.org/10.1016/j.tips.2013.01.001</url>
    <description>Berk, M., Malhi, G. S., Gray, L. J., &amp; Dean, O. M. (2013). The promise of N-acetylcysteine in neuropsychiatry. Trends in Pharmacological Sciences, 34(3), 167-177.</description>
  </link>
  <link>
    <url>https://doi.org/10.1080/10715762.2018.1468564</url>
    <description>Aldini, G., Altomare, A., Baron, G., Vistoli, G., Carini, M., Borsani, L., &amp; Sergio, F. (2018). N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radical Research, 52(7), 751-762</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 13, 2021</study_first_submitted>
  <study_first_submitted_qc>February 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>February 21, 2021</last_update_submitted>
  <last_update_submitted_qc>February 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Sherien Emara</investigator_full_name>
    <investigator_title>Teaching Assistant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

